Sunshine Novo (688621.SH): Clinical trial application for the investigational project BTP0427 has been approved.

Zhitong Finance APP News, Sunshine Novo (688621.SH) announced that recently, the company and its wholly-owned subsidiary Jiangsu Novo Biotech New Drug R&D Co., Ltd. received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, and the clinical trial application for the company's ongoing project BTP0427 has been approved. BTP0427 is intended for the treatment of chronic heart failure with reduced ejection fraction, suitable for symptomatic treatment of chronic heart failure patients with cardiac systolic dysfunction, and as a replacement therapy for patients who have already received combination treatment with the same dose of beta-blockers and sinoatrial node If current inhibitors and whose condition is controlled.